全文获取类型
收费全文 | 307篇 |
免费 | 19篇 |
专业分类
耳鼻咽喉 | 3篇 |
儿科学 | 10篇 |
妇产科学 | 6篇 |
基础医学 | 37篇 |
口腔科学 | 5篇 |
临床医学 | 42篇 |
内科学 | 53篇 |
皮肤病学 | 14篇 |
神经病学 | 16篇 |
特种医学 | 4篇 |
外科学 | 29篇 |
综合类 | 1篇 |
一般理论 | 1篇 |
预防医学 | 41篇 |
眼科学 | 14篇 |
药学 | 21篇 |
中国医学 | 2篇 |
肿瘤学 | 27篇 |
出版年
2023年 | 3篇 |
2021年 | 11篇 |
2020年 | 9篇 |
2019年 | 5篇 |
2018年 | 21篇 |
2017年 | 5篇 |
2016年 | 8篇 |
2015年 | 12篇 |
2014年 | 13篇 |
2013年 | 17篇 |
2012年 | 26篇 |
2011年 | 33篇 |
2010年 | 17篇 |
2009年 | 12篇 |
2008年 | 19篇 |
2007年 | 22篇 |
2006年 | 10篇 |
2005年 | 7篇 |
2004年 | 12篇 |
2003年 | 8篇 |
2002年 | 12篇 |
1996年 | 1篇 |
1995年 | 3篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1988年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1978年 | 1篇 |
1962年 | 1篇 |
1961年 | 1篇 |
1949年 | 1篇 |
1948年 | 2篇 |
1947年 | 1篇 |
1945年 | 1篇 |
1942年 | 3篇 |
1941年 | 1篇 |
1940年 | 3篇 |
1939年 | 1篇 |
1938年 | 2篇 |
1937年 | 1篇 |
1934年 | 1篇 |
1933年 | 1篇 |
1932年 | 1篇 |
1931年 | 3篇 |
1930年 | 1篇 |
1929年 | 1篇 |
1924年 | 2篇 |
1922年 | 1篇 |
1914年 | 1篇 |
排序方式: 共有326条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
Jinhan Xie MPharm PhD Amit Kumar PhD M. Emmy M. Dolman PhD Chelsea Mayoh BSc Dong-Anh Khuong-Quang MD PhD Roxanne Cadiz BSc Marie Wong-Erasmus PhD Emily V. A. Mould PhD Dylan Grebert-Wade BSc Paulette Barahona PhD Alvin Kamili BMedSc PhD Maria Tsoli PhD Timothy W. Failes PhD Shu-Oi Chow BSc Greg M. Arndt BSc PhD Kanika Bhatia MD Glenn M. Marshall AM MB BS MD FRACP David S. Ziegler MBBS BSc FRACP MD Michelle Haber AM PhD Hon DSc FAHMS Richard B. Lock BSc PhD Vanessa Tyrrell BAppSc MHGSA FHGSA MBA CSA ARCPA Loretta Lau MBBS MMed PhD FRACP Penny Athanasatos BAppSc CT CF Andrew J. Gifford BSc Hons PhD MBBS FRCPA 《Cancer cytopathology》2021,129(10):805-818
5.
Yu Ueda PhD Satoru Takahashi MD PhD Naoki Ohno PhD Katsusuke Kyotani RT Hideaki Kawamitu MS Tosiaki Miyati PhD Nobukazu Aoyama RT Yoshiko Ueno MD PhD Kazuhiro Kitajima MD PhD Fumi Kawakami MD Tomoyuki Okuaki MS Ryuko Tsukamoto MT Emmy Yanagita MT Kazuro Sugimura MD PhD 《Journal of magnetic resonance imaging : JMRI》2016,43(1):138-148
6.
Andrea Beaton Emmy Okello Twalib Aliku Sulaiman Lubega Peter Lwabi Charles Mondo Robert McCarter Craig Sable 《Pediatric cardiology》2014,35(7):1259-1267
Screening with portable echocardiography has uncovered a large burden of latent rheumatic heart disease (RHD) among asymptomatic children in endemic regions, the significance of which remains unclear. This study aimed to determine the 2-year outcomes for children with latent RHD diagnosed by echocardiographic screening. Children identified with latent RHD enrolled in a biannual follow-up program. Risk factors for disease persistence and progression were examined. Of 62 children, 51 (82 %) with latent RHD had a median follow-up period of 25 months. Of these 51 children, 17 (33.3 %) reported an interval sore throat or symptoms consistent with acute rheumatic fever (ARF). Of 43 children initially classified as having borderline RHD, 21 (49 %) remained stable, 18 (42 %) improved (to no RHD) and 4 (10 %) worsened to definite RHD. Of the 8 children initially classified as having definite RHD, 6 (75 %) remained stable, and 2 (25 %) improved to borderline RHD. Two children had confirmed episodes of recurrent ARF, one of which represented the sole case of clinical worsening. The risk factors for disease persistence or progression included younger age (p = 0.05), higher antistreptolysin O titers at diagnosis (p = 0.05), and more morphologic valve abnormalities (p = 0.01). After 2 years, most of the children had a benign course, with 91 % remaining stable or showing improvement. Education may improve recognition of streptococcal sore throat. Longer-term follow-up evaluation, however, is warranted to confirm disease progression and risk factor profile. This could help tailor screening protocols for those at highest risk. 相似文献
7.
8.
Geurt Stokman Yu Qin Tijmen H. Booij Sreenivasa Ramaiahgari Marie Lacombe M. Emmy M. Dolman Kim M.A. van Dorenmalen Gwendoline J.D. Teske Sandrine Florquin Frank Schwede Bob van de Water Robbert J. Kok Leo S. Price 《Journal of the American Society of Nephrology : JASN》2014,25(7):1474-1485
Activation of Rap1 by exchange protein activated by cAMP (Epac) promotes cell adhesion and actin cytoskeletal polarization. Pharmacologic activation of Epac-Rap signaling by the Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP during ischemia-reperfusion (IR) injury reduces renal failure and application of 8-pCPT-2′-O-Me-cAMP promotes renal cell survival during exposure to the nephrotoxicant cisplatin. Here, we found that activation of Epac by 8-pCPT-2′-O-Me-cAMP reduced production of reactive oxygen species during reoxygenation after hypoxia by decreasing mitochondrial superoxide production. Epac activation prevented disruption of tubular morphology during diethyl maleate–induced oxidative stress in an organotypic three-dimensional culture assay. In vivo renal targeting of 8-pCPT-2′-O-Me-cAMP to proximal tubules using a kidney-selective drug carrier approach resulted in prolonged activation of Rap1 compared with nonconjugated 8-pCPT-2′-O-Me-cAMP. Activation of Epac reduced antioxidant signaling during IR injury and prevented tubular epithelial injury, apoptosis, and renal failure. Our data suggest that Epac1 decreases reactive oxygen species production by preventing mitochondrial superoxide formation during IR injury, thus limiting the degree of oxidative stress. These findings indicate a new role for activation of Epac as a therapeutic application in renal injury associated with oxidative stress.Renal ischemia-reperfusion (IR) injury is an important cause of AKI1 and a significant risk factor for the development of renal dysfunction after kidney transplantation.2 During IR injury, morphologic and functional alterations of the proximal tubular epithelium occur that are linked to the development of renal failure and activation of immune cells via release of proinflammatory cytokines.3Exchange protein activated by cAMP (Epac) is a guanine nucleotide exchange factor for the small GTPase Rap1.4 Activation of Epac by cAMP or by the Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP (also referred to as 007) induces functional activation of Rap1.5 Initial studies showed that Epac-Rap signaling enhances cell adhesion by supporting maturation of cell-cell junctions6,7 and promoting integrin-mediated cell-matrix adhesion.8,9 In line with these studies, we recently demonstrated that selective activation of Epac reduces proximal tubular epithelial cell (PTEC) detachment during IR injury using in vitro and in vivo models.10 Activation of Epac-Rap was associated with reduced expression of markers for cellular stress in PTECs. In addition, in vitro cisplatin-induced apoptosis of PTECs could be significantly reduced by activation of Epac and this was also associated with improved adhesion of cells.11 On the basis of these findings, we hypothesized that activation of Epac-Rap signaling may protect against a common cytotoxic event in these injury models.Unbalanced and uncontrolled production of reactive oxygen species (ROS) is an important mediator of cell injury and occurs during cisplatin nephrotoxicity,12 IR injury,13 and renal fibrosis.14 In renal pathology, intracellular ROS can be produced enzymatically such as by NADPH oxidase (NOX) complexes or derive from dysfunctional mitochondrial activity. Mitochondrial ROS production appears to be the driving force behind hypoxia-reoxygenation cell injury15 and cisplatin cytotoxicity.16Here we studied the role of specific proximal tubular activation of Epac and how this protects against renal injury in both in vitro and in vivo models for IR injury. We found that ROS production during reoxygenation after hypoxia was decreased by activation of Epac. Selective proximal tubular activation of Epac by renal targeting of 8-pCPT-2′-O-Me-cAMP conjugated to lysozyme (LZM-007) reduced oxidative stress in an in vivo model for IR injury and significantly decreased IR injury–associated renal failure and tubular damage. Our data show that Epac activation reduces ROS-mediated cellular injury in renal disease and may be a therapeutic strategy for modulation of oxidative stress. 相似文献
9.
Immunohistochemical expression profiles of solute carrier transporters in alpha‐fetoprotein‐producing gastric cancer 下载免费PDF全文
10.
Katja Närhi Ashwini S Nagaraj Elina Parri Riku Turkki Petra W van Duijn Annabrita Hemmes Jenni Lahtela Virva Uotinen Mikko I Mäyränpää Kaisa Salmenkivi Jari Räsänen Nina Linder Jan Trapman Antti Rannikko Olli Kallioniemi Taija M Af Hällström Johan Lundin Wolfgang Sommergruber Simon Anders Emmy W Verschuren 《The Journal of pathology》2018,245(1):101-113
A key question in precision medicine is how functional heterogeneity in solid tumours informs therapeutic sensitivity. We demonstrate that spatial characteristics of oncogenic signalling and therapy response can be modelled in precision‐cut slices from Kras‐driven non‐small‐cell lung cancer with varying histopathologies. Unexpectedly, profiling of in situ tumours demonstrated that signalling stratifies mostly according to histopathology, showing enhanced AKT and SRC activity in adenosquamous carcinoma, and mitogen‐activated protein kinase (MAPK) activity in adenocarcinoma. In addition, high intertumour and intratumour variability was detected, particularly of MAPK and mammalian target of rapamycin (mTOR) complex 1 activity. Using short‐term treatment of slice explants, we showed that cytotoxic responses to combination MAPK and phosphoinositide 3‐kinase–mTOR inhibition correlate with the spatially defined activities of both pathways. Thus, whereas genetic drivers determine histopathology spectra, histopathology‐associated and spatially variable signalling activities determine drug sensitivity. Our study is in support of spatial aspects of signalling heterogeneity being considered in clinical diagnostic settings, particularly to guide the selection of drug combinations. © 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. 相似文献